

# **Erosive esophagitis - Pipeline Insight, 2021**

https://marketpublishers.com/r/E5F53CD6EF6EEN.html

Date: September 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: E5F53CD6EF6EEN

## **Abstracts**

This report can be delivered to the clients within 24 hours

DelveInsight's, "Erosive esophagitis - Pipeline Insight, 2021," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Erosive esophagitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Erosive esophagitis Understanding

Erosive esophagitis: Overview

Erosive Esophagitis (EE) is a major type of gastroesophageal reflux disease (GERD), characterized by erosions in the gastric mucosa caused by acidic reflux of stomach contents into the esophagus. The symptoms of EE include: difficult swallowing, painful swallowing, chest pain, swallowed food becoming stuck in the esophagus (food impaction), heartburn, and acid regurgitation. A diagnosis of EE is based upon a thorough clinical evaluation and physical examination. Tests like Barium X-ray and endoscopy are done. Laboratory tests are done to check for Infectious esophagitis. Treatment for Erosive Esophagitis is based on treating the underlying cause of disorder, use of therapies intended to lessen symptoms, and to manage complications. Medications involved over-the-counter treatments like antacids (Maalox, Mylanta etc.),



H-2-receptor blockers, such as cimetidine and ranitidine, proton pump inhibitors, such as lansoprazole and omeprazole, and Potassium-competitive acid blockers are used.

'Erosive esophagitis - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Erosive esophagitis pipeline landscape is provided which includes the disease overview and Erosive esophagitis treatment guidelines. The assessment part of the report embraces, in depth Erosive esophagitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Erosive esophagitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

## Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Erosive esophagitis R&D. The therapies under development are focused on novel approaches to treat/improve Erosive esophagitis.

Erosive esophagitis Emerging Drugs Chapters

This segment of the Erosive esophagitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Erosive esophagitis Emerging Drugs

Fexuprazan: Neurogastrx

Fexuprazan is a potassium?competitive acid pump antagonist, which reversibly blocks the proton pump that secretes gastric acids located in the cannalicular membrane. It is a next-generation of proton pump inhibitors (PPI) and is under Phase III clinical development in patients with erosive esophagitis.



YYD601: YooYoung Pharmaceutical

YYD601 (Esomeprazole magnesium dehydrate) is a leading proton pump inhibitor. The drug is being developed by YooYoung Pharmaceutical for the treatment of peptic ulcer and gastro-oesophageal reflux disease. The therapy is currently under Phase III clinical development for the treatment of Erosive esophagitis.

Further product details are provided in the report.

Erosive esophagitis: Therapeutic Assessment

This segment of the report provides insights about the different Erosive esophagitis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Erosive esophagitis

There are approx. 3+ key companies which are developing the therapies for Erosive esophagitis. The companies which have their Erosive esophagitis drug candidates in the most advanced stage, i.e. Phase III include, Neurogastrx.

**Phases** 

DelveInsight's report covers around 3+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of


Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates



### Route of Administration

Erosive esophagitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as



Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Erosive esophagitis: Pipeline Development Activities



The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Erosive esophagitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Erosive esophagitis drugs.

Erosive esophagitis Report Insights

Erosive esophagitis Pipeline Analysis

Therapeutic Assessment

**Unmet Needs** 

Impact of Drugs

Erosive esophagitis Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

**Unmet Needs** 

**Key Questions** 

Current Treatment Scenario and Emerging Therapies:



How many companies are developing Erosive esophagitis drugs?

How many Erosive esophagitis drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Erosive esophagitis?

What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Erosive esophagitis therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Erosive esophagitis and their status?

What are the key designations that have been granted to the emerging drugs?

## **Key Players**

Eisai

Daewoong Pharmaceutical

YooYoung Pharmaceutical

### **Key Products**

Azeloprazole

Fexuprazan

**YYD601** 



## **Contents**

Introduction

**Executive Summary** 

Erosive esophagitis: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Erosive esophagitis – DelveInsight's Analytical Perspective

Late Stage Products (Phase III)

Comparative Analysis

YYD601: YooYoung Pharmaceutical

**Product Description** 

Research and Development

**Product Development Activities** 

Drug profiles in the detailed report.

Mid Stage Products (Phase II)

Comparative Analysis

Azeloprazole: Eisai

**Product Description** 

Research and Development

**Product Development Activities** 

Drug profiles in the detailed report.

Early Stage Products (Phase I)

Comparative Analysis

Drug name: Company name

**Product Description** 

Research and Development



**Product Development Activities** 

Drug profiles in the detailed report.

Preclinical/Discovery Stage Products

**Comparative Analysis** 

Drug name: Company name

**Product Description** 

Research and Development

**Product Development Activities** 

Drug profiles in the detailed report.

**Inactive Products** 

Comparative Analysis

Erosive esophagitis Key Companies

Erosive esophagitis Key Products

Erosive esophagitis- Unmet Needs

Erosive esophagitis- Market Drivers and Barriers

Erosive esophagitis- Future Perspectives and Conclusion

Erosive esophagitis Analyst Views

**Appendix** 



## **List Of Tables**

#### LIST OF TABLES

Table 1	Total	<b>Products</b>	for	Frosive	esonha	aitis
Table I	i Otai	1 100000	101	LIUSIVE	Coopila	gitio

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

**Table 12 Inactive Products** 



# **List Of Figures**

### LIST OF FIGURES

Figure 1	Total	<b>Products</b>	for F	rosive	esopl	nadi	itis
i igaio i	i Otai	1 100000	101 6	_100100	CCCPI	IUU	1110

- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products



### I would like to order

Product name: Erosive esophagitis - Pipeline Insight, 2021

Product link: <a href="https://marketpublishers.com/r/E5F53CD6EF6EEN.html">https://marketpublishers.com/r/E5F53CD6EF6EEN.html</a>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

# **Payment**

First name: Last name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <a href="https://marketpublishers.com/r/E5F53CD6EF6EEN.html">https://marketpublishers.com/r/E5F53CD6EF6EEN.html</a>

To pay by Wire Transfer, please, fill in your contact details in the form below:

Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

& Conditions at https://marketpublishers.com/docs/terms.html

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms